JAK2 and acute lymphoblastic leukemia: A variety of genetic alterations that lead to gene fusions that are sensitive to tyrosine kinase inhibitors (e.g., ABL1 and PDGFRB rearrangements) or JAK inhibitors (e.g., JAK2, EPOR, IL7R rearrangements) have been described in recent years for the group of BCR/ABL1-like ALL [12,13,14,15,16].